Connect Biopharma Holdings (CNTB) Net Cash Flow (2024 - 2026)

Connect Biopharma Holdings has disclosed Net Cash Flow across 3 years of filings, most recently posting -$19.1 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 161.11% year-over-year to -$19.1 million; the TTM figure through Jun 2026 stood at -$13.8 million (up 79.95% YoY), while the FY2025 annual figure was -$40.3 million, down 50.15% from the prior year.
• Net Cash Flow came in at -$19.1 million for Q2 2026 at Connect Biopharma Holdings, down from $7.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $8.7 million in Q1 2024 to a low of -$30.6 million in Q1 2025.
• Average Net Cash Flow over 3 years is -$7.9 million, with a median of -$5.8 million recorded in 2024.
• Year-over-year, Net Cash Flow slumped 453.37% in 2025 and soared 124.89% in 2026.
• Over 3 years, Net Cash Flow stood at -$18.0 million in 2024, then surged by 102.5% to $449000.0 in 2025, then tumbled by 4345.88% to -$19.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$19.1 million in Q2 2026, $7.6 million in Q1 2026, and $449000.0 in Q4 2025.